1. Home
  2. PXLW vs SCYX Comparison

PXLW vs SCYX Comparison

Compare PXLW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pixelworks Inc.

PXLW

Pixelworks Inc.

N/A

Current Price

$7.07

Market Cap

42.3M

Sector

Technology

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$5.30

Market Cap

44.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PXLW
SCYX
Founded
1997
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.3M
44.4M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
PXLW
SCYX
Price
$7.07
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $36.33
AVG Volume (30 Days)
24.6K
★ 196.0K
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.36
EPS
★ 12.07
N/A
Revenue
★ $693,000.00
$257,000.00
Revenue This Year
$58.73
N/A
Revenue Next Year
$63.64
$906.41
P/E Ratio
$0.57
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.84
$0.57
52 Week High
$15.42
$6.09

Technical Indicators

Market Signals
Indicator
PXLW
SCYX
Relative Strength Index (RSI) 54.72 52.75
Support Level $5.60 $4.65
Resistance Level $7.16 $5.56
Average True Range (ATR) 0.26 0.39
MACD -0.01 0.03
Stochastic Oscillator 62.34 74.53

Price Performance

Historical Comparison
PXLW
SCYX

About PXLW Pixelworks Inc.

Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: